19072 Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth
factor receptor (EGFR) mutation show excellent response to gefitinib, but eventually develop …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib
and erlotinib, are known to play a significant role in EGFR mutation‑positive non‑small cell …

Background: The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) erlotinib is difficult to be accurately assessed in patients with non-small cell …

7085 Background: The EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib induce
significant regressions and improve survival in patients with NSCLC. Mutations in the EGFR …

18081 Background: Somatically acquired mutations in the EGFR gene in non-small cell lung
cancer are associated with a significant clinical response to gefitinib, a tyrosine kinase …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and
erlotinib are known to have greater efficacy in EGFR mutation-positive non-small cell lung …

Objective Somatic mutations in the epidermal growth factor receptor gene are associated
with a therapeutic response to epidermal growth factor receptor tyrosine kinase inhibitors …

BACKGROUND: This study prospectively assessed the efficacy of gefitinib and the survival
benefit for non-small cell lung cancer (NSCLC) patients with epidermal growth factor …

Purpose To evaluate the relationship between the epidermal growth factor receptor (EGFR)
mutation status and the effectiveness of gefitinib monotherapy or chemotherapy in patients …